News
TNYA
4.845
+4.87%
0.225
Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual Meeting
Tenaya Therapeutics, Inc. Will present seven abstracts at the American Society of Gene and Cell Therapy's 27th Annual Meeting in May 2024. The company's mission is to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease.
Barchart · 1d ago
Weekly Report: what happened at TNYA last week (0422-0426)?
Weekly Report · 4d ago
Weekly Report: what happened at TNYA last week (0415-0419)?
Weekly Report · 04/22 09:24
Weekly Report: what happened at TNYA last week (0408-0412)?
Weekly Report · 04/15 09:22
Weekly Report: what happened at TNYA last week (0401-0405)?
Weekly Report · 04/08 09:24
Institutions along with private equity firms who hold considerable shares inTenaya Therapeutics, Inc. (NASDAQ:TNYA) come under pressure; lose 10% of holdings value
Private equity firms hold 44% of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) The top 4 shareholders of the company hold more than half of the stock. The company has a large number of institutional investors, but the majority of shares are held by private equity firms. The majority of the business is held by the top four shareholders. TenayaTherapeutics has a history of insider buying and selling, but there are 5 warning signs it may be over-valued. It's worth looking at Tenayatherapeutics's earnings history to see if insiders are buying or selling.
Simply Wall St · 04/07 13:02
Tenaya Therapeutics’ Strategic Advantages in Cardiovascular Genetic Medicine Garner Buy Rating
TipRanks · 04/05 10:56
Weekly Report: what happened at TNYA last week (0325-0329)?
Weekly Report · 04/01 09:23
Optimistic Buy Rating for Tenaya Therapeutics Based on Promising Gene Therapy Pipeline and Upcoming Clinical Milestones
TipRanks · 03/28 11:05
Weekly Report: what happened at TNYA last week (0318-0322)?
Weekly Report · 03/25 09:24
Tenaya Therapeutics Price Target Maintained With a $20.00/Share by Chardan Capital
Dow Jones · 03/21 17:02
Chardan Capital Reiterates Buy on Tenaya Therapeutics, Maintains $20 Price Target
Benzinga · 03/21 16:52
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Vera Therapeutics (VERA), Tyra Bioscience (TYRA) and Tenaya Therapeutics (TNYA)
Analysts have new ratings on Vera Therapeutics, Tyra Bioscience and Tenaya Therapeutic. The Healthcare sector has been in the spotlight recently. Wedbush maintained a Hold rating on VeraTherapeutics today and set a price target of $34.00. Tenaya has an analyst consensus of Strong Buy.
TipRanks · 03/21 12:50
Buy Rating Affirmed for Tenaya Therapeutics: A Combination of Solid Financials and Promising Clinical Pipeline
TipRanks · 03/21 06:17
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 03/21 03:50
Analysts Are Bullish on These Healthcare Stocks: Tenaya Therapeutics (TNYA), Telix Pharmaceuticals Ltd. (TLPPF)
TipRanks · 03/21 03:40
Analysts Offer Insights on Healthcare Companies: Sera Prognostics (SERA) and Tenaya Therapeutics (TNYA)
TipRanks · 03/21 02:50
Analysts Are Bullish on Top Healthcare Stocks: Tenaya Therapeutics (TNYA), Sera Prognostics (SERA)
TipRanks · 03/21 02:30
Tenaya Therapeutics Price Target Cut to $18.00/Share From $19.00 by Canaccord Genuity
Dow Jones · 03/20 11:54
Tenaya Therapeutics Is Maintained at Buy by Canaccord Genuity
Dow Jones · 03/20 11:54
More
Webull provides a variety of real-time TNYA stock news. You can receive the latest news about Tenaya Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About TNYA
Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. The Company is advancing a pipeline of novel therapies with diverse treatment modalities for rare genetic cardiovascular disorders and more prevalent heart conditions. The Company’s advanced product candidates include TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed to treat the underlying cause of MYBPC3 associated HCM by delivering a working MYBPC3 gene to specific cells of the heart via a single infusion. TN-401 is the Company’s adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene. TN-301 is a small molecule for heart failure with preserved ejection fraction.